Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yale University
The purpose of this prospective, non-interventional study is to perform neurological and cognitive assessment of breast cancer patients who receive standard of care single agent weekly paclitaxel or docetaxel chemotherapy to determine the onset and severity of chemotherapy induced neuropathy (CIPN) and cognitive impairment (CICI).
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women ages 18 to 70 with histologically confirmed clinically stage I-III breast cancer who will receive weekly paclitaxel (80 mg/m2) or docetaxel (60-100mg/m2) chemotherapy as part of their routine care.
You may not be if
diabetes mellitus
prior history of neuropathy or symptoms of numbness or peripheral pain, or prior neurotoxic chemotherapy.
current symptoms of numbness and neuropathic pain
treatment for bipolar disease
treatment or concomitant use of common medications used to treat neuropathic pain, such as amitriptyline, gabapentin, pregabalin, duloxetine, for any indication
limited English that would preclude understanding and completion of the study questionnaires
pregnancy
life expectancy \<12 weeks
Clareo Health | Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients
